|
ESC Congress in Stockholm: From genes to outcomes
- ESC 2010 Congress Spotlight by Fausto Pinto, CPC Chairman
- Impact of genotype on outcomes in the CURE ACTIVE study (Efficacy and
Safety of Clopidogrel compared with Placebo according to CYP2C19 Genotype in
over 6000 patients with Non-ST-elevation Acute Coronary Syndromes and atrial
fibrillation) (Guillaume Paré, Hamilton)
- Genetic profiling: ready for clinical use? (Gilles Montalescot, Paris)
- Genetic determinants of treatment benefit of ACE-inhibitor therapy in
patients with stable coronary artery disease (Jasper Brugts, Rotterdam)
|
|
ESC Congress in Stockholm: Acute Coronary Syndrome
- RIKS HIA: Survival benefits by 12 years registry supported improvement of
acute cardiac care in the Sweden - the RIKS-HIA 12 years study (Tomas
Jernberg, Stockholm)
- New ESC Guidelines: ESC/EACTS Guidelines on myocardial revascularisation
(William Winjs, Aalst and Philippe Kolh, Liege)
- The HEBE III trial (A single dose of erythropoietin in ST-elevation
myocardial infarction) (Adriaan Voors, Groningen)
- Clinical applications of remote conditionning (Hans Erick Botker, Skejby)
|
|
ESC Congress in Stockholm: Interventional cardiology
- The LESSON I study (Long-term comparison of Everolimus-eluting and
Sirolimus-eluting Stents for cOronary revascularization) (Stephan Windecker,
Bern)
- The ATOLL trial (an international, randomized trial comparing i.v.
enoxaparin with i.v. unfractionated heparin in primary PCI for ST+
myocardial infarction) (Gilles Montalescot, Paris)
- EHS ACS III: Euro Heart Survey Acute Coronary Syndromes III (François
Schiele, Besançon)
|
|
ESC Congress in Stockholm: Hypertension and risk factors management
- Catheter-based renal denervation increases insulin sensitivity and
improves glucose metabolsim in patients with resistant hypertension (Felix
Mahfoud, Homburg)
- Reduction in mortality with antihypertensive agents. Evidence from
clinical trials in at-risk hypertensive patients (Michel Bertrand, Lille)
- The RESPONSE study (effect of a nurse coordinated prevention program on
cardiovascular risk after an acute coronary syndrome: Main results of the
RESPONSE trial) (Ron Peters, Amsterdam)
|
|
ESC Congress in Stockholm: What's new this year
- What¹s new@ESC 2010 by Fausto Pinto, CPC Chairman
- The best of the EHJ: new dimensions in CV imaging (Jeroen Bax, Leiden)
- Meet the humanitarian mission: Chain of Hope (Magdi Yacoub, London),
Bambini Cardiopatici Nel Mondo (Alessandro Frigiola, Milan) and La Chaîne de
l¹Espoir (Alain Deloche, Paris).
- European Association of Echocardiography educational ressources (Andreas
Hagendorff, Leipzig)
- HeartScore demo (Ian Graham, Dublin)
- ESC 2011 by Michel Komajda, ESC President.
|
| |
ESC Congress in Stockholm: Atrial fibrillation
- New ESC Guidelines on Atrial fibrillation (John Camm, London)
- The ANTIPAF trial (Angiotensin II-antagonist in paroxysmal atrial
fibrillation trial) (Stuart Connolly, Hamilton)
- The AVERROES study (Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent
Strokes) (Andreas Goette, Emmenbruecke)
|
|
ESC Congress in Stockholm: Chronic heart failure
- The SHIFT study (Effects of ivabradine on cardiovascular events in
patients with moderate to severe chronic heart failure and left ventricular
systolic dysfunction) (Michel Komajda, Paris)
- New ESC Guidelines on device therapy in heart failure (Kenneth Dickstein,
Stavanger)
- The new ESC observational research programme - The heart failure Registry
(Aldo Pietro Maggioni, Florence)
|
| |
|
ESC Congress in Stockholm - day 1
- Welcome message from Roberto Ferrari, ESC President
- The 2010 Scientific Programme overview with Fausto Pinto, Chairman of the Congress Programme Committee
- ESC for Primary Care Physicians and Nurses
|
|
|
ESC Congress in Stockholm - day 2
- The best of ESC Hot Line I
SHIFT (Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction)
HEBE III: A single dose of erythropoietin in ST-elevation myocardial infarction
- ESC 2010 Spotlight « CAD, from genes to CV outcomes » - Is genetic profiling for antiplatelet therapy ready for clinical use to individualised management
- New ESC Guidelines: atrial fibrillation
|
|
|
ESC Congress in Stockholm - day 3
- Best of Hot Line II - LESSON I 2010
- Focused Update of ESC guidelines on device therapy in heart failure
- The best of the European Heart Journal on cardiovascular imaging
- European Association of Echocardiography educational resources
|
| |
|
ESC Congress in Stockholm - day 4
- Best of ESC Hot Line III: RESPONSE (Effect of a nurse coordinated prevention program on cardiovascular risk after an acute coronary syndrome).
- New ESC Guidelines: ESC/EACTS Guidelines on myocardial revascularisation
- Meet the humanitarian mission: Chain of Hope, Bambini Cardiopatici Nel Mondo and La Chaîne de l?Espoir.
- ESC 2011 by Pr Michel Komajda, ESC President.
|